The research work was carried out using Ultraviolet (UV)—visible spectroscopy and Reverse Phase-Ultra Fast Liquid Chromatography (RP-UFLC) for establishing novel methods for the analysis and quantification of Biosimilar drug, Etanercept. The maximum absorbance of Etanercept was found to be 215 nm and it obeyed Beer-Lamberts law in the range of 5 to 200 μg/ml and 1 to 32 μg/ml for UV and RP-UFLC, respectively. The correlation coefficient (r2) value was found to be between 0.999 and 0.9995. All the validation parameters like linearity, accuracy, and precision, Limit of Detection (LOD), Limit of Quantitation (LOQ) and Robustness were found to be within acceptance criteria as per ICH guidelines. The results of accuracy studies (99.0% to 100.38%) indicated the methods to be accurate. The RSD % for interday and intraday precision studies was found to be less than 2%. Robustness and ruggedness were expressed in terms of RSD % which were also in the specified limits. LOD and LOQ of proposed method was calculated and found to be 1.257 and 3.809 μg/ml by UV, and 0.1073 μg/ml and 0.3251 μg/ml by RP-UFLC method, respectively. The developed methods were observed to be simple, rapid and cost-efficient. It can be easily applied for the estimation of Etanercept in the marketed formulations and for routine analysis of the Biosimilar drug.
References
[1]
Nupur, N., Singh, S.K., Narula, G. and Rathore, A.S. (2016) Assessing Analytical Comparability of Biosimilars: GCSF as a Case Study. Journal of Chromatography B, 1032, 165-171. https://doi.org/10.1016/j.jchromb.2016.05.027
[2]
Burness, C.B. and Duggan, S.T. (2016) Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases. BioDrugs, 30, 371-378. https://doi.org/10.1007/s40259-016-0188-z
[3]
Scott, L.J. (2014) Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases. Drugs, 74, 1379-1410. https://doi.org/10.1007/s40265-014-0258-9
[4]
Nast, A., Gisondi, P., Ormerod, A.D., Saiag, P., Smith, C., Spuls, P., et al. (2015) European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris—Update 2015—Short Version—EDF in Cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology, 29, 2277-2294. https://doi.org/10.1111/jdv.13354
[5]
Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., et al. (2011) 2010 Update of the ASAS/EULAR Recommendations for the Management of Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 70, 896-904. https://doi.org/10.1136/ard.2011.151027
[6]
Gossec, L., Smolen, J.S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., et al. (2016) European League against Rheumatism (EULAR) Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2015 Update. Annals of the Rheumatic Diseases, 75, 499-510. https://doi.org/10.1136/annrheumdis-2015-208337
[7]
Minota, S. (2013) Physico-Chemical Characteristics of TNFa Blockers and Their Effectiveness in the Treatment of Rheumatoid Arthritis: The Theoretical and Real worlds. Modern Rheumatology, 23, 1034-1036. https://doi.org/10.3109/s10165-012-0744-4
[8]
Strand, V., Girolomoni, G., Schiestl, M., Mayer, R.E., Friccius-Quecke, H. and McCamish, M. (2017) The Totality-of-the-Evidence Approach to the Development and Assessment of GP2015, a Proposed Etanercept Biosimilar. Current Medical Research and Opinion, 33, 993-1003. https://doi.org/10.1080/03007995.2017.1288612
[9]
Smolen, J.S., Landewe, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., et al. (2014) EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2013 Update. Annals of the Rheumatic Diseases, 73, 492-509. https://doi.org/10.1136/annrheumdis-2013-204573
[10]
Smolen, J.S., Aletaha, D., Bijlsma, J.W.J., Breedveld, F.C., Boumpas, D., Burmester, G., et al. (2010) Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force. Annals of the Rheumatic Diseases, 69, 631-637. https://doi.org/10.1136/ard.2009.123919
[11]
Neovius, M., Arkema, E.V., Olsson, H., Eriksson, J.K., Kristensen, L.E., Simard, J.F., et al. (2015) Drug Survival on TNF Inhibitors in Patients with Rheumatoid Arthritis Comparisons of Adalimumab, Etanercept and Infliximab. Annals of the Rheumatic Disease, 74, 354-360. https://doi.org/10.1136/annrheumdis-2013-204128
[12]
Goffe, B. and Cather, J.C. (2003) Etanercept: An Overview. Journal of the American Academy of Dermatology, 49, 105-111. https://doi.org/10.1016/mjd.2003.554
[13]
Chiran, D.A., Litscher, G., Weber, M., Ailioaie, L.M., Ailioaie, C. and Litscher, D. (2013) Intravenous Laser Blood Irradiation Increases Efficacy of Etanercept in Selected Subtypes of Juvenile Idiopathic Arthritis: An Innovative Clinical Research Approach. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 168134. https://doi.org/10.1155/2013/168134
[14]
Lamanna, W.C., Mayer, R.E., Rupprechter, A., Fuchs, M., Higel, F., Fritsch, C., Vogelsang, C., Seidl, A., Toll, H., Schiestl, M. and Holzmann, J. (2017) The Structure-Function Relationship of Disulfide Bonds in Etanercept. Scientific Reports, 7, Article No. 3951. https://doi.org/10.1038/s41598-017-04320-5
[15]
Campanati, A., Diotallevi, F., Martina, E., Paolinelli, M., Radi, G. and Offidani, A. (2020) Safety Update of Etanercept Treatment for Moderate to Severe Plaque Psoriasis. Expert Opinion on Drug Safety, 19, 439-448. https://doi.org/10.1080/14740338.2020.1740204
[16]
Cho, I.H., Lee, N., Song, D., Jung, S.Y., Bou-Assaf, G., Sosic, Z., Zhang, W. and Lyubarskaya, Y. (2016) Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB4, a Biosimilar of Etanercept. mAbs, 8, 1136-1155. https://doi.org/10.1080/19420862.2016.1193659
[17]
Maarschalkerweerd, A.V., Wolbink, G.J., Stapel, S.O., Jiskoot, W. and Hawe, A. (2011) Comparison of Analytical Methods to Detect Instability of Etanercept during Thermal Stress Testing. European Journal of Pharmaceutics and Biopharmaceutics, 78, 213-221. https://doi.org/10.1016/j.ejpb.2011.01.012
[18]
Yamanaka, H., Kamatani, N., Tanaka, Y., Hibino, T., Drescher, E., Sánchez-Bursón, J., Rettenbacher, M., Bhatia, G., Gadve, S., Shah, C. and Bakhle, D. (2020) A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 7, 149-163. https://doi.org/10.1007/s40744-019-00186-3
[19]
European Directorate for the Quality of Medicines (2019) European Pharmacopoeia 10.0: Etanercept. Stationery Office, Strasbourg, 2566-2570.
[20]
Houel, S., Hilliard, M., Yu, Y.Q., McLoughlin, N., Martin, S.M., Rudd, P.M., Williams, J.P. and Chen, W. (2014) N- and O-glycosylation Analysis of Etanercept Using Liquid Chromatography and Quadrupole Time-of-Flight Mass Spectrometry Equipped with Electron-Transfer Dissociation Functionality. Analytical Chemistry, 86, 576-584. https://doi.org/10.1021/ac402726h
[21]
Victor, P.M.M., Abad-Javier, M.E., Romero-Díaz, A.J., Villaseñor-Ortega, F., Pérez, N.O., Flores-Ortiz, L.F. and Medina-Rivero, E. (2014) Comparability of a Three-Dimensional Structure in Biopharmaceuticals Using Spectroscopic Methods. Journal of Analytical Methods in Chemistry, 2014, Article ID: 950598. https://doi.org/10.1155/2014/950598
[22]
Yi, S., Kim, S.E., Park, M.K., Yoon, S.H., Cho, J.Y., Lim, K.S., Shin, S.G., Jang, I.J. and Yu, K.S. (2012) Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®): A Double-Blind, Single-Dose, Crossover Study in Healthy Volunteers. BioDrugs, 26, 177-184. https://doi.org/10.2165/11631860-000000000-00000
[23]
Miranda-Hernández, M.P., López-Morales, C.A., Perdomo-Abúndez, F.C., Salazar-Flores, R.D., Ramírez-Ibanez, N.D., Pérez, N.O., Pérez, A.M., Revilla-Beltri, J., Flores-Ortiz, L.F. and Medina-Rivero, E. (2016) New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept. Journal of Immunology Research, 2016, Article ID: 9697080. https://doi.org/10.1155/2016/9697080
[24]
Richter, O.V., Skerjanec, A., Afonso, M., Heinrich, S.S., Poetzl, J., Woehling, H., Velinova, M., Koch, A., Kollins, D., Macke1, L. and Wuerth, G. (2017) GP2015, a Proposed Etanercept Biosimilar: Pharmacokinetic Similarity to Its Reference Product and Comparison of Its Autoinjector Device with Prefilled Syringes. British Journal of Clinical Pharmacology, 83, 732-741. https://doi.org/10.1111/bcp.13170
[25]
Christof, F., Wohlschlager, T., Holzmann, J. and Huber, C.G. (2017) A Generic HPLC Method for Absolute Quantification of Oxidation in Monoclonal Antibodies and FC-Fusion Proteins Using UV and MS Detection. Analytical Chemistry, 89, 8391-8398. https://doi.org/10.1021/acs.analchem.7b01755
